CUPR Cuprina Holdings (Cayman) LTD Annual reports only
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1995704 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 · USD | FY20242024-12-31 · USD | FY20232023-12-31 · SGD | FY20222022-12-31 · SGD |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $38,789 | $35,522 | 100,773 | 56,599 |
| Cost of revenue | $39,290 | $37,745 | 64,168 | 36,621 |
| Gross profit | -$501 | -$2,223 | 36,605 | 19,978 |
| R&D expense | $176,385 | $177,433 | 167,734 | 292,879 |
| SG&A expense | $3.58M | $1.03M | 937,200 | 902,887 |
| Operating income | -$3.75M | -$1.21M | -1.07M | -1.18M |
| Interest expense | $11,447 | $1,311 | 727 | 1,842 |
| Pretax income | -$3.58M | -$1.11M | -1.09M | -1.09M |
| Net income | -$3.63M | -$1.15M | -1.12M | -1.09M |
| EBITDA | -$3.73M | -$1.18M | -1.03M | -1.15M |
| EPS (basic) | -17.75 | -6.38 | -6.22 | -6.08 |
| EPS (diluted) | -17.75 | -6.38 | -6.22 | -6.08 |
| Weighted avg. shares (diluted) | 20.47M | 18.00M | 18.00M | 18.00M |
| Banking | ||||
| Net interest income | -$11,447 | -$27,354 | -56,587 | -2,017 |
| Provision for credit losses | -$2,960 | -$1,553 | 106 | -2,935 |
| Balance sheet | ||||
| Cash & equivalents | $2.42M | $85,622 | 35,263 | — |
| Receivables | $14,163 | $19,399 | 50,819 | — |
| Inventory | — | $1,272 | 7,665 | — |
| Current assets | $5.70M | $1.22M | 1.44M | — |
| PP&E, net | $60,270 | $42,685 | 78,366 | — |
| Total assets | $6.61M | $1.28M | 1.59M | — |
| Current liabilities | $2.42M | $4.44M | 4.43M | — |
| Short-term debt | $30,108 | $40,616 | — | — |
| Long-term debt | $98,112 | $120,362 | — | — |
| Total debt | $128,220 | $160,978 | — | — |
| Total liabilities | $2.68M | $4.56M | 4.48M | — |
| Shareholders' equity | $3.93M | -$3.28M | -2.99M | -1.78M |
| Net debt | -$2.30M | $75,356 | — | — |
| Cash flow statement | ||||
| Operating cash flow | -$7.10M | -$908,609 | -894,981 | -1.85M |
| Capital expenditure | $45,268 | $16,088 | 67,977 | 16,049 |
| Free cash flow | -$7.15M | -$924,697 | -962,958 | -1.87M |
| Investing cash flow | -$45,268 | -$16,088 | -67,977 | -31,284 |
| Financing cash flow | $9.51M | $985,795 | 433,075 | 1.68M |
| Depreciation & amortization | $28,394 | $31,012 | 35,059 | 29,088 |
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.